Canopy Growth diluted existing shareholders to pull off a recent acquisition.
It is now the top medical cannabis company by revenue in Canada.
However, it remains a struggling business with dim prospects.
Canopy Growth (NASDAQ: CGC) has had a terrible go of it in the past five years. Despite the cannabis industry experiencing regulatory progress in Canada and elsewhere, the company's financial results have been subpar at best, while it has lost significant market value. Could Canopy Growth bounce back? The pot grower recently made an acquisition it hopes will be the spark it needs to turn things around. Let's find out whether there are brighter days ahead for Canopy Growth following this acquisition.
Image source: Getty Images.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
On March 16, Canopy Growth completed the acquisition of MTL Cannabis, a Canadian company. MTL's portfolio of products and brands included pre-rolls, vape cartridges, dried flower, and more. It also operates in Quebec, the second-largest cannabis market in Canada, where Canopy Growth will now have a stronger presence thanks to the acquisition. According to Canopy Growth, this move makes it the leading medical cannabis company in the country by revenue. However, it wasn't a cheap transaction for Canopy Growth. The total equity value of the deal was about $125 million, but Canopy Growth paid for the transaction in a mix of cash and stock and chose to issue new shares to do so.
Canopy Growth has not performed well over the past few years due to challenges in its home country. Even though cannabis is legal in Canada, there remains substantial regulatory oversight that has slowed the market's progress. That's not to mention the oversupply issues stemming from significant competition in Canada. The result has been slow sales growth (at best) and consistent red ink on the bottom line.

CGC Revenue (Annual) data by YCharts
Canopy Growth's buyout of MTL Cannabis isn't the first time it has tried to improve its financial results and market position through an acquisition, but past attempts have had little success. In my view, this one will be no different. Meanwhile, Canopy Growth's issuance of new shares to fund this transaction further dilutes existing shareholders. Perhaps it would be worth it if we could reasonably expect that Canopy Growth's financial results would meaningfully improve as a result.
But beyond an immediate spike in top-line growth from the acquisition, the business's underlying fundamentals might not change much. Further, Canopy Growth is facing other issues. The company recently announced that it had identified accounting errors in several of its past financial statements and now intends to refile. While management stated that this would not affect key metrics such as revenue, gross margins, and net income or losses, it's not a good look, especially for a company struggling on multiple fronts.
So, what's the verdict? Canopy Growth is operating in a challenging-to-navigate industry with uncertain prospects, generates poor financial results, and is forced to significantly dilute existing shareholders for an acquisition that may not move the needle nearly as much as it hopes, given the challenges in Canada. For all those reasons (and more), it's best to avoid this stock.
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $449,393!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,366,006!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 3, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.